Overview

Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. Here we tried to classify TAK patients in 3 levels, including mild, moderate, and severe, and prescribe methotrexate and tofacitinib randomly in mild and moderate patients, to observe the relatively better treatment strategy, facilitating better intervention strategy in TAK patients.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai Zhongshan Hospital
Treatments:
Methotrexate
Tofacitinib